ONS-5010: The First On-Label Bevacizumab Treatment for Wet AMD
Time: 9:30 am
day: Day One
Details:
- Addressing regulatory challenges to meet FDA approval
- Leveraging EMA support to establish ONS-5010 as a global standard for wet AMD treatment
- Explaining the product details, offering an affordable and effective alternative to compete in the crowded anti-VEGF market and reshape retinal care paradigms
